Lithotripsy (ESWL) — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Extracorporeal shock wave lithotripsy (ESWL) is a non-invasive urological procedure that uses high-energy acoustic (sound) waves generated outside the body and focused precisely on kidney or ureteral stones to fragment them into small particles (ideally 2–4 mm) that can pass spontaneously through the urinary tract in the urine. The shock waves are generated by an electromagnetic, electrohydraulic, or piezoelectric source within the lithotriptor machine and focused on the stone using either fluoroscopic (X-ray) or ultrasound targeting systems. When the focused shock wave reaches the stone, it creates tensile and compressive forces that exceed the stone's mechanical tensile strength, causing fragmentation. The technique was first introduced clinically in 1980 at the University of Munich and rapidly replaced many open and endoscopic stone procedures due to its non-invasive nature and outpatient delivery. ESWL is most effective for stones in the renal pelvis, upper ureter, and mid-ureter. It is the least invasive urological stone treatment available and is the preferred first-line approach for eligible stones (5–20 mm, radiopaque, non-impacted) in the renal pelvis and proximal ureter according to EAU and AUA guidelines. The procedure is performed in a dedicated lithotriptor room under the care of a urologist.

ESWL is indicated for kidney and ureteral stones meeting specific anatomical and compositional eligibility criteria. Primary candidacy criteria include: stone size 5–20 mm in the renal pelvis or calices; proximal and mid ureteral stones up to 10 mm; stones that are radiopaque or visible on ultrasound (allowing targeting); and patients without the contraindications listed below. ESWL is less effective and alternative treatments are preferred for: stones larger than 2 cm (PCNL is preferred — stone-free rates 85–95% vs. 60–70% for ESWL); lower pole calyceal stones (stone-free rate 35–60% due to gravity-impaired fragment clearance); very hard stones (calcium oxalate monohydrate, cystine, or brushite compositions) that resist acoustic fragmentation; impacted stones causing hydronephrosis; and anatomatically abnormal kidneys (horseshoe, malrotated). Absolute contraindications: pregnancy (radiation exposure); uncorrected coagulation disorder or anticoagulation therapy (warfarin, DOAC — must be stopped 3–7 days before treatment); untreated urinary tract infection; abdominal aortic or renal artery aneurysm in or near the shock wave path; and pacemakers or implantable defibrillators (relative contraindication — cardiologist assessment required). Urological review and KUB X-ray or low-dose CT urogram characterise the stone before planning.

The patient lies supine or prone on the lithotriptor table depending on the machine design. A ureteral stent (Double-J stent, 4.7–6 French) is sometimes placed cystoscopically before ESWL for large stones or solitary kidney patients to ensure continued urine drainage if stone fragments cause transient obstruction (steinstrasse formation). Under sedation or light general anaesthesia, the stone is localised using fluoroscopic (X-ray) or ultrasound targeting on the machine's gantry. The patient is positioned so the stone coincides exactly with the machine's focal point — this targeting accuracy is essential for treatment efficacy. Treatment begins at a low shock wave energy (starting power), increased gradually over the first 200–400 shocks (ramping) to minimise renal trauma and allow tissue accommodation. Between 1,500 and 3,500 shock waves are delivered at a rate of 60–120 per minute over 45–60 minutes. The stone's fragmentation is monitored by real-time fluoroscopy or serial imaging. If the stone moves significantly, repositioning is required. Post-ESWL, a plain X-ray (KUB) confirms stone fragmentation. Patients are discharged the same day with a urine strainer (paper filter) to collect fragments and identify stone composition by chemical analysis. A course of alpha-blocker therapy (tamsulosin 400 mcg daily) facilitates passage of fragments by relaxing ureteral smooth muscle.

ESWL achieves stone-free rates of 80–85% for renal pelvis stones less than 2 cm at 3 months — defined as no residual fragments or fragments less than 4 mm on CT. Stones 1–2 cm in the renal pelvis have the highest stone-free rates (75–90%); lower pole stones 1–2 cm have substantially lower rates (35–60%) due to poor drainage of fragments. The primary advantage of ESWL over ureteroscopy and PCNL is complete non-invasiveness — no surgical incision, no endoscopic instrumentation of the urinary tract, no anaesthetic requirement in many cases, and same-day outpatient treatment. This results in lower complication rates, no catheterisation, and rapid return to normal activity. ESWL can be repeated if initial fragmentation is incomplete — up to 3 sessions per stone episode are generally performed, with each session spaced at least 2 weeks apart to allow renal healing. After successful fragmentation, stone fragments typically pass over 2–6 weeks, with 90% clearing by 3 months. Tamsulosin MR 400 mcg daily significantly facilitates fragment passage and reduces colic episodes.

ESWL is the safest urological stone procedure but carries specific complication risks. Renal parenchymal haemorrhage (bruising within the kidney substance) occurs in virtually all patients but is clinically significant (subcapsular haematoma causing haematuria, loin pain, and occasionally flank haematoma) in 1–2%; severe haemorrhage requiring transfusion or embolisation is rare (<0.1%). Perinephric haematoma is identified on ultrasound or CT in 0.2–0.5% of patients. Ureteral colic from stone fragment passage causes severe loin-to-groin pain in 15–30% of patients in the 2–4 weeks after ESWL — managed with NSAIDs (diclofenac), opioids, and alpha-blockers. Steinstrasse ('stone street') — a column of stone fragments impacted in the ureter — occurs in 4–7% of treated patients, particularly after treatment of large stones; most resolve spontaneously or with repeat ESWL, but 1–2% require ureteroscopy. Sepsis from fragmentation of an infected stone is a serious complication (0.5–1%) requiring emergency hospitalisation and intravenous antibiotics. Incomplete fragmentation requiring additional sessions affects 20–25% of patients. Long-term renal parenchymal scarring from repeated high-energy sessions is a theoretical concern; current evidence suggests no significant long-term reduction in renal function when treatment protocols are followed.

Patients are observed for 1–2 hours post-ESWL in the recovery unit before discharge. Most return home the same day. Macroscopic haematuria (pink-tinged or red urine) on the day of treatment is expected and resolves within 24 hours. A urine strainer is provided to collect stone fragments; fragments are sent for compositional analysis to guide dietary and metabolic prevention strategies. High fluid intake — 2–3 litres daily — is essential throughout the stone passage period (2–6 weeks) to flush fragments through the urinary tract. Activity can resume the following day for most patients; heavy lifting and vigorous exercise are avoided for 48 hours. Paracetamol and an NSAID (diclofenac 50 mg three times daily if no contraindications) manage colic pain from fragment passage. Tamsulosin MR 400 mcg at night is continued for 2–4 weeks. A follow-up KUB X-ray or ultrasound at 4–6 weeks assesses stone clearance and identifies residual fragments requiring additional ESWL or ureteroscopy. Stone prevention advice (high fluid intake, dietary oxalate restriction for calcium oxalate stones, reduced dietary sodium, targeted supplement based on 24-hour urine metabolic profile) is provided to reduce recurrence.